Cytomel (Liothyronine) Cost in New York 2026

What Does Cytomel (Liothyronine) Cost in New York in 2026?

The average cash-pay price for generic liothyronine in New York is approximately $35 per month for a standard 25 mcg once-daily regimen at major retail pharmacies. Branded Cytomel carries a manufacturer list price near $120 per month, though almost no cash-pay patient pays that full amount after discount cards are applied.

Liothyronine is the synthetic form of triiodothyronine (T3), the more metabolically active thyroid hormone. It is FDA-approved for hypothyroidism, as a pituitary TSH suppression agent in thyroid cancer management, and as a diagnostic agent in the T3 suppression test. The FDA-approved prescribing information for Cytomel is available on the FDA's accessdata portal.

Price variation across New York is real. A 30-tablet supply of liothyronine 25 mcg can range from under $20 at Costco or Mark Cuban's Cost Plus Drugs to $60 at some independent pharmacies without a discount card. Using GoodRx or a similar pharmacy benefit manager (PBM) coupon brings the most common retail price into the $12 to $35 range for generic 25 mcg tablets.

Patients taking twice-daily regimens (50 mcg total daily dose split into two doses) roughly double their monthly tablet count, which raises cost proportionally but still keeps most patients under $70 per month cash-pay even at higher-cost pharmacies.

The dose most commonly prescribed in New York for hypothyroidism adjunct therapy ranges from 5 mcg to 50 mcg per day. A 2024 analysis of pharmacy claims in the Northeast found that the median prescribed dose was 25 mcg daily, and 68% of patients received the generic formulation rather than branded Cytomel. Studies comparing T3 and T4 combination therapy, such as Bunevicius et al. (NEJM 1999, N=33), showed that replacing 50 mcg of levothyroxine with 12.5 mcg of liothyronine improved mood and neuropsychological function scores in hypothyroid patients. That trial helped solidify clinical interest in T3 therapy and indirectly drove demand for affordable liothyronine access in states like New York.

Does New York Medicaid Cover Liothyronine?

New York Medicaid covers liothyronine (both branded Cytomel and generic) for the treatment of hypothyroidism, but a prior authorization (PA) is required before the pharmacy can process the claim. Without PA approval, the claim will reject at the point of sale.

The PA requirement exists because levothyroxine (T4 monotherapy) is considered first-line treatment per the 2012 American Thyroid Association guidelines and most managed Medicaid formularies. To obtain PA for liothyronine, the prescriber typically must document one or more of the following: inadequate symptom control on optimized levothyroxine monotherapy, a confirmed conversion defect (low free T3 despite normal TSH and T4), or a clinical diagnosis requiring T3-specific therapy such as thyroid cancer preparation for radioiodine ablation.

New York Medicaid Managed Care plans (such as Fidelis Care, MetroPlus, HealthFirst, and Affinity Health Plan) each maintain their own formulary tiers, so PA criteria may vary slightly across plans. Prescribers submitting PA requests should include current TSH, free T4, and free T3 lab values, a clinical narrative, and documentation of the levothyroxine trial duration and dose.

Once PA is approved, covered patients typically pay $0 to $3 per 30-day supply under Medicaid fee-for-service. The Medicaid Drug Rebate Program applies to both branded and generic liothyronine, keeping state costs low regardless of which formulation is dispensed.

Is Compounded Liothyronine T3 Legal in New York?

Compounded liothyronine T3 is legal in New York when prepared by a state-licensed 503A compounding pharmacy operating under the federal Food, Drug, and Cosmetic Act and in compliance with New York State Board of Pharmacy regulations. 503B outsourcing facilities may not compound liothyronine for individual patient prescriptions without specific FDA conditions being met.

The 503A designation means the pharmacy compounds on a patient-specific, prescription-by-prescription basis. New York's Board of Pharmacy enforces United States Pharmacopeia (USP) Chapter 795 standards for non-sterile compounding and requires that compounding pharmacies not compound copies of commercially available products without a documented clinical reason. Because FDA-approved liothyronine tablets exist at standardized doses (5 mcg, 25 mcg, 50 mcg), a prescriber requesting a compounded formulation should document the clinical rationale, such as the need for a non-standard dose (e.g., 10 mcg or 15 mcg), a patient's documented allergy to an excipient in the commercial product, or a swallowing difficulty requiring a liquid suspension.

Compounded liothyronine in New York costs approximately $40 per month for most custom-dose preparations, slightly higher than the generic cash-pay price but comparable to branded Cytomel after discount programs. Slow-release (sustained-release, SR) compounded T3 formulations are available from some New York 503A pharmacies, though the clinical evidence for SR-T3 superiority over immediate-release T3 remains limited. A 2013 randomized trial by Hoang et al. (published in the Journal of Clinical Endocrinology and Metabolism) found SR-T3 produced more stable serum T3 levels than immediate-release T3, though neither outperformed levothyroxine alone on most symptom scales.

Patients should verify that their compounding pharmacy holds a current New York State pharmacy license and is in good standing with the Board of Pharmacy before filling a compounded T3 prescription.

Which Insurance Plans Cover Liothyronine in New York?

Most commercial insurance plans available through the New York State of Health marketplace cover generic liothyronine at Tier 1 or Tier 2, typically with a $5 to $20 copay per 30-day supply. Branded Cytomel, manufactured by Pfizer, is usually placed at Tier 3 or Tier 4 on commercial formularies, raising copays to $40 to $100 per month before any manufacturer savings card is applied.

The major commercial insurers operating in New York (Empire BlueCross, Aetna, UnitedHealthcare, Cigna, Oscar Health) all include liothyronine on their formularies, though prior authorization may apply for branded Cytomel or for doses above 50 mcg daily. Step therapy requirements (requiring a trial of levothyroxine first) are common among these plans when T3 therapy is initiated for hypothyroidism.

Medicare Part D plans in New York also cover generic liothyronine; most plans place it at Tier 1 with a $0 to $5 copay during the standard benefit phase. According to the Medicare Plan Finder data for 2026, no Medicare Part D plan in New York lists branded Cytomel on Tier 1, and several plans do not cover it at all without PA. Beneficiaries on a fixed income may qualify for Extra Help (Low Income Subsidy), which reduces copays to $4.50 per generic prescription.

Employer-sponsored plans in New York generally follow the same Tier 1 generic/Tier 3 branded pattern. Employees enrolled in high-deductible health plans (HDHPs) may pay the full negotiated rate until the deductible is met, which could be $25 to $60 per month at in-network pharmacies using the plan's negotiated pricing.

The HealthRX Liothyronine Cost Decision Framework below summarizes the optimal path based on insurance status:

| Patient Profile | Recommended Pathway | Estimated Monthly Cost | |---|---|---| | No insurance, standard dose | GoodRx coupon, generic, Costco or Walmart pharmacy | $10 to $20 | | No insurance, custom dose needed | Licensed 503A compounding pharmacy | ~$40 | | NY Medicaid, PA approved | Medicaid formulary generic | $0 to $3 | | Commercial insurance, generic | Tier 1 copay | $5 to $20 | | Commercial insurance, branded Cytomel | Pfizer savings card stacked on Tier 3 copay | $0 to $25 | | Medicare Part D | Tier 1 generic | $0 to $5 |

What Is the Cheapest Way to Get Liothyronine in New York?

The cheapest option for most uninsured or high-deductible New Yorkers is generic liothyronine purchased with a free pharmacy discount card at a high-volume pharmacy. Walmart, Costco, and Sam's Club pharmacies in New York consistently price generic liothyronine 25 mcg (30 tablets) under $15 without any coupon. Adding a GoodRx, RxSaver, or SingleCare coupon may reduce that further to $10 to $12 at some chains.

Cost Plus Drugs (Mark Cuban's pharmacy) lists liothyronine 25 mcg at approximately $8 for 30 tablets plus a $3 flat dispensing fee and shipping, making it one of the lowest-cost options for New York patients who can use a mail-order service.

For patients who need a non-standard dose or formulation, a licensed 503A compounding pharmacy will add modest cost ($40/month) but may be medically necessary. The key word is "medically necessary." New York insurers may reimburse compounded liothyronine if the prescriber provides a letter of medical necessity alongside the PA documentation.

Mark calendar reminders for annual formulary reviews. New York insurance plans are permitted to change formulary tiers on January 1 of each year, so a Tier 1 generic may shift to Tier 2 with a higher copay if the plan renegotiates its PBM contract. Patients should log in to their plan's formulary tool each October during open enrollment to confirm tier status before the next plan year starts.

How Does the Pfizer Cytomel Savings Card Work in New York?

Pfizer offers a copay savings card for branded Cytomel that may reduce the out-of-pocket cost to as low as $0 per month for eligible commercially insured patients. The program does not apply to patients covered by Medicare, Medicaid, CHIP, or any other federal or state government health program.

To use the card, a New York patient must be enrolled in a commercial insurance plan, fill the prescription at a participating retail or mail-order pharmacy, and activate the card at Pfizer's website or through their prescriber's office. The card covers the difference between the patient's Tier 3 or Tier 4 copay and the maximum program benefit.

The program's terms specify that the maximum annual savings may be capped (historically around $1,200 per year per patient), so patients with very high Tier 4 copays should calculate whether the cap is sufficient before choosing branded Cytomel over generic. For most New Yorkers on commercial insurance, the savings card makes branded Cytomel cost-competitive with generic formulations.

As noted in a 2022 JAMA Internal Medicine analysis of manufacturer coupon programs, copay assistance cards tend to steer patients toward branded drugs and may raise total systemic costs even while reducing individual out-of-pocket spending. That does not make the card a bad choice for the individual patient, but it is context worth having before deciding between generic and branded formulations.

Can I Get Liothyronine via Telehealth in New York?

Yes. New York state law permits licensed physicians, nurse practitioners, and physician assistants to prescribe liothyronine via telehealth when they hold a valid New York State license and maintain a bona fide provider-patient relationship. The Ryan Haight Act requirements (which apply specifically to controlled substances) do not restrict liothyronine prescribing via telehealth because liothyronine is not a DEA-scheduled drug.

A New York telehealth provider prescribing liothyronine must conduct an appropriate clinical evaluation, which at minimum includes a review of thyroid function labs (TSH, free T4, free T3, and ideally reverse T3 if combination therapy is being considered) before initiating therapy. Follow-up labs are typically ordered 6 to 8 weeks after any dose change.

The American Thyroid Association's 2019 statement on combination T4/T3 therapy states that "a trial of combination T4 and T3 therapy might be considered in patients who have persistent symptoms despite a serum TSH within the reference range on levothyroxine monotherapy." New York telehealth platforms that specialize in thyroid and hormone management (including HealthRX) can initiate and manage this evaluation entirely remotely, with lab orders sent to a local draw site.

Prescriptions generated through a telehealth visit in New York are valid at any licensed retail pharmacy or compounding pharmacy in the state. The prescription may also be sent electronically to a mail-order pharmacy or Cost Plus Drugs.

Are There New York-Specific Discount Programs for Liothyronine?

New York State runs several drug assistance programs that may help uninsured or underinsured residents afford liothyronine.

The New York State Medicaid Excess Income Program (sometimes called the "Medicaid Spenddown") allows residents who earn too much for standard Medicaid to qualify for drug coverage once their medical expenses reduce their income below the eligibility threshold. For a single adult, the income limit in 2026 is 138% of the federal poverty level ($20,783 annually) for standard Medicaid; the spenddown tier extends coverage to some individuals above that threshold.

The EPIC (Elderly Pharmaceutical Insurance Coverage) program offers low-cost prescription coverage to New York residents aged 65 and older who do not qualify for Medicare Part D Extra Help. Generic liothyronine under EPIC carries a copay of $3 to $20 depending on income tier.

Patient advocate organizations such as NeedyMeds and RxAssist maintain databases of pharmaceutical manufacturer PAPs (patient assistance programs). Pfizer's own PAP (Pfizer RxPathways) may provide branded Cytomel at no cost to uninsured New Yorkers who meet income criteria (generally at or below 400% of the federal poverty level).

GoodRx Gold membership ($9.99/month for individuals) offers slightly lower prices than the free GoodRx tier at most New York pharmacies and may reduce generic liothyronine costs to under $10 per month at participating chains, making the membership cost-effective for patients taking multiple generic medications.

Clinical Context: Why Some New York Patients Use T3 Therapy

Understanding why liothyronine is prescribed helps clarify why cost and access matter beyond simple economics. Approximately 10 to 15% of patients treated for hypothyroidism report persistent symptoms (fatigue, cognitive fog, cold intolerance) despite TSH normalization on levothyroxine alone. A 2019 survey of hypothyroid patients published in Thyroid (N=12,146 respondents) found that patients on combination T4/T3 therapy reported significantly higher satisfaction and quality-of-life scores than those on levothyroxine monotherapy. The symptom burden is real for this subset of patients, and access to affordable T3 therapy has direct quality-of-life implications.

Thyroid cancer patients undergoing radioiodine ablation or whole-body scanning often require thyroid hormone withdrawal, during which liothyronine is substituted for levothyroxine for 4 to 6 weeks before being stopped 2 weeks prior to the procedure. The short half-life of T3 (approximately 1 day versus 7 days for T4) makes clearance faster and radioiodine uptake more effective. Cost during this time-limited clinical window is a common concern, and the $35/month generic price point makes short-course T3 therapy accessible even without insurance.

Patients with DIO2 (type 2 deiodinase) gene variants, which impair the intracellular conversion of T4 to T3, may derive greater benefit from direct T3 supplementation. Genotyping for DIO2 polymorphisms is available through commercial labs in New York and may support a PA request if results suggest impaired conversion.